Early real-world outcomes of intravitreal aflibercept 8 mg in treatment-Naïve neovascular AMD: AI-assisted fluid volume analysis
Abstract Background This study was conducted as a retrospective, exploratory analysis to assess early anatomical and functional effects of intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (nAMD) in a small cohort of patients. Methods This retrospective study was conducte...
Saved in:
| Main Authors: | Jennifer Cattaneo, Eva C. De Oliveira Figueiredo, Andrea Montesel, Sandra Vermeirsch, Chiara M. Eandi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | International Journal of Retina and Vitreous |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40942-025-00665-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Two-year results of switching to intravitreal administration of faricimab in patients with aflibercept-refractory neovascular age-related macular degeneration
by: Masaaki Saito, et al.
Published: (2025-08-01) -
Early Real-World Outcomes of Switching to 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration in the United Kingdom
by: Muiz Musadiq, et al.
Published: (2025-06-01) -
Aflibercept high-dose (8mg) related intraocular inflammation (IOI) – a case series
by: Laura Hoffmann, et al.
Published: (2024-12-01) -
Efficacy and Safety of Aflibercept Biosimilars Relative to Reference Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis
by: Aljuhani HS, et al.
Published: (2025-06-01) -
Early optical coherence tomography biomarkers for tailored frequency of intravitreal aflibercept in neovascular age-related macular degeneration
by: Gyeongsoo Lim, et al.
Published: (2025-03-01)